Risk of Hemolytic Anemia in IBD Patients with Glucose-6-Phosphate Dehydrogenase Deficiency Treated with Mesalamine: Results of a Retrospective-Prospective and Ex Vivo Study.
5-ASA
glucose-6-phosphate dehydrogenase deficiency
hemolytic anemia
inflammatory bowel disease
mesalamine
sulfasalazine
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
20 Jul 2023
20 Jul 2023
Historique:
received:
12
06
2023
revised:
03
07
2023
accepted:
18
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Mesalamine is one of the most-used drugs in inflammatory bowel disease (IBD), especially ulcerative colitis. Regulatory agencies have listed mesalamine as an unsafe drug in subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency based on the risk of hemolysis, although scientific evidence is lacking. The occurrence of acute and/or chronic hemolytic anemia in IBD patients with G6PD deficiency exposed to mesalamine was evaluated. In this multicenter study, IBD patients with G6PD deficiency (cases) receiving mesalamine were retrospectively evaluated for acute, and prospectively for chronic, hemolysis. The presence of hemolytic anemia was based on red blood cell and reticulocyte count, hemoglobin, lactate dehydrogenase, unconjugated bilirubin, and haptoglobin levels. Cases were compared with controls (IBD patients with normal G6PD). A total of 453 IBD patients (mean age 52.1 ± 16.0 years; 58.5% female) were enrolled. Ulcerative colitis was present in 75% of patients. G6PD deficiency was detected in 17% of patients. Oral mesalamine was used in 67.9% of ulcerative colitis and in 32.4% of Crohn's disease cases. None of the 78 IBD patients with G6PD deficiency receiving mesalamine underwent hospitalization or specific treatment for acute hemolytic anemia. Relevant differences in chronic hemolysis markers were not observed in 30 cases compared with 112 controls receiving mesalamine (≤4500 mg/day). Marker modifications were also observed in mesalamine-free cases, consistent with the basal rate of erythrophagocytosis in G6PD deficiency. Ex vivo experiments showed the release of methemoglobin by G6PD deficient RBCs upon mesalamine challenge, only above 2.5 mg/mL, a concentration never reached in the clinical setting. This study provides, for the first time, evidence that mesalamine is safe in G6PD deficiency at a dosage of up to 4500 mg/day.
Sections du résumé
BACKGROUND
BACKGROUND
Mesalamine is one of the most-used drugs in inflammatory bowel disease (IBD), especially ulcerative colitis. Regulatory agencies have listed mesalamine as an unsafe drug in subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency based on the risk of hemolysis, although scientific evidence is lacking. The occurrence of acute and/or chronic hemolytic anemia in IBD patients with G6PD deficiency exposed to mesalamine was evaluated.
METHODS
METHODS
In this multicenter study, IBD patients with G6PD deficiency (cases) receiving mesalamine were retrospectively evaluated for acute, and prospectively for chronic, hemolysis. The presence of hemolytic anemia was based on red blood cell and reticulocyte count, hemoglobin, lactate dehydrogenase, unconjugated bilirubin, and haptoglobin levels. Cases were compared with controls (IBD patients with normal G6PD).
RESULTS
RESULTS
A total of 453 IBD patients (mean age 52.1 ± 16.0 years; 58.5% female) were enrolled. Ulcerative colitis was present in 75% of patients. G6PD deficiency was detected in 17% of patients. Oral mesalamine was used in 67.9% of ulcerative colitis and in 32.4% of Crohn's disease cases. None of the 78 IBD patients with G6PD deficiency receiving mesalamine underwent hospitalization or specific treatment for acute hemolytic anemia. Relevant differences in chronic hemolysis markers were not observed in 30 cases compared with 112 controls receiving mesalamine (≤4500 mg/day). Marker modifications were also observed in mesalamine-free cases, consistent with the basal rate of erythrophagocytosis in G6PD deficiency. Ex vivo experiments showed the release of methemoglobin by G6PD deficient RBCs upon mesalamine challenge, only above 2.5 mg/mL, a concentration never reached in the clinical setting.
CONCLUSIONS
CONCLUSIONS
This study provides, for the first time, evidence that mesalamine is safe in G6PD deficiency at a dosage of up to 4500 mg/day.
Identifiants
pubmed: 37510911
pii: jcm12144797
doi: 10.3390/jcm12144797
pmc: PMC10381559
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Aliment Pharmacol Ther. 2010 Jan 15;31(2):202-9
pubmed: 19891667
J Gastroenterol Hepatol. 2021 Jan;36(1):137-143
pubmed: 32525567
Eur J Clin Chem Clin Biochem. 1996 May;34(5):431-8
pubmed: 8790979
Antioxidants (Basel). 2023 Jan 31;12(2):
pubmed: 36829893
N Engl J Med. 2009 Nov 19;361(21):2066-78
pubmed: 19923578
J Clin Invest. 1982 Feb;69(2):494-7
pubmed: 6120182
Lancet. 2012 Nov 3;380(9853):1606-19
pubmed: 22914296
JAMA. 1968 Aug 12;205(7):528-30
pubmed: 4386139
Cochrane Database Syst Rev. 2012 Oct 17;10:CD000544
pubmed: 23076890
Inflamm Bowel Dis. 2016 Aug;22(8):1793-802
pubmed: 27416043
J Pharmacol Exp Ther. 1995 Jan;272(1):399-406
pubmed: 7815356
Blood. 2020 Sep 10;136(11):1225-1240
pubmed: 32702756
Clin Pharmacol Ther. 2023 May;113(5):973-985
pubmed: 36049896
Blood. 2012 Nov 15;120(20):4123-33
pubmed: 22993389
Am J Gastroenterol. 2018 Apr;113(4):481-517
pubmed: 29610508
Br J Clin Pharmacol. 2021 Mar;87(3):1141-1149
pubmed: 32671846
Gastroenterology. 1990 May;98(5 Pt 1):1162-9
pubmed: 1969825
Ann Ist Super Sanita. 1999;35(2):193-203
pubmed: 10645652
PLoS Med. 2012;9(11):e1001339
pubmed: 23152723
Hum Genet. 1993 Apr;91(3):293-4
pubmed: 8478015
Bull World Health Organ. 1989;67(6):601-11
pubmed: 2633878
J Immunol. 1996 Mar 1;156(5):1937-41
pubmed: 8596047
Gene Geogr. 1990 Dec;4(3):139-42
pubmed: 2129615
Br J Haematol. 2020 Apr;189(1):24-38
pubmed: 31991476
Can J Gastroenterol. 2010 Feb;24(2):127-33
pubmed: 20151072
Mol Med Rep. 2016 Aug;14(2):1726-32
pubmed: 27356773